Becton Dickinson andNYSE: BDX

BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.

BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine FRANKLIN LAKES, N.J. , June 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.

NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Becton, Dickinson and Company (NYSE: BDX). The settlement provides for a fund of $85,000,000 to benefit class members.

BD's (BDX) robust product portfolio raises optimism about the stock.

Shares of Edwards Lifesciences Corp. EW, -1.14% rallied 3% in premarket trading Monday, after the company announced an agreement to sell its critical care product group to Becton Dickinson & Co. BDX, +2.29% in a cash deal valued at $4.2 billion. Edwards said it plans to use the proceeds from the sale to fund investments for growth, such as in technologies for technologies for aortic, mitral, tricuspid and pulmonic patients, and in therapeutic areas for interventional heart failure.

Combination unlocks new future value-creation opportunities and is expected to be immediately accretive to BD revenue growth, adjusted gross margin, adjusted operating margin and adjusted EPS Expands BD's portfolio of smart connected care solutions with complementary and broad set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline Critical Care to operate as a separate business unit within BD's Medical segment, based in Irvine, Calif. and led by Katie Szyman FRANKLIN LAKES, N.J.

The FDA's approval of BD's use of self-collected vaginal specimens for HPV testing is expected to expand screening availability to more women.

The Zacks Style Scores, a key feature of the Zacks Premium research service, can help investors of all types - whether they focus on value, growth, or momentum - identify strong stocks more easily.

The latest figures for Becton Dickinson (BDX) provide a glimpse into the company's performance in the first quarter of 2024, but it could be beneficial to analyze certain key metrics in comparison to Wall Street predictions and last year's results.